Drew Deniger compensation by year
Alaunos Therapeutics Summary Compensation Table · all 2 fiscal years held| Component | FY2022 | FY2023 |
|---|---|---|
| Salary | $345,572 | $317,757 |
| Bonus | $103,672 | $103,672 |
| Stock awards | $0 | $0 |
| Option awards | $481,229 | $47,888 |
| Non-equity incentive | $0 | $0 |
| Pension and deferred compensation | $0 | $0 |
| All other | $18,640 | $264,035 |
| Total | $949,113 | $733,352 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Alaunos Therapeutics, Inc. DEF 14A filed May 21, 2025, accession 0001193125-25-123677, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Alaunos Therapeutics, Inc. filed document, accession 0001193125-25-123677. Every figure is read from that document and cited to the page and table it appears in. Filed May 21, 2025.
Equity holdings
unvested awards at FY2022 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 2,812 | $1,828 | — |
| Option | 9,375 | — | $4.13 |
| Option | 31,250 | — | $2.82 |
| Option | 285,938 | — | $2.11 |
| Option | 17,500 | — | $4.31 |
| Option | 187,500 | — | $1.50 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Alaunos Therapeutics, Inc.'s FY2022 proxy; value at the fiscal year-end close, as the company printed it.
Alaunos Therapeutics’s named executive officers, FY2023
as the company reported each| Named executive officer | Role | FY2023 total |
|---|---|---|
| Kevin Boyle | Former Chief Executive Officer | $1,986,946 |
| Melinda Lackey | SVP, Legal & Administration | $831,737 |
| Drew Deniger · this page | Former VP, Research and Development | $733,352 |
| Dale Hogue | Interim Chief Executive Officer | $48,153 |
The full Alaunos Therapeutics compensation record
free company briefThis page is one person within Alaunos Therapeutics's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Alaunos Therapeutics proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Alaunos Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.